SEC Form 4 · accession 0001123292-19-000435
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Murray
Officer — President and CEO · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $4.57 | Mar 1, 2019 | A | 357,500 | A | — | Mar 1, 2029 | Common Shares | 357,500 | 357,500 | D |
Explanation of responses
- F1The option will vest and become exercisable in three equal annual installments beginning March 1, 2020.